Cytokinetics INC Form 4 insider transactions

Cytokinetics' EVP of Research & Development, Fady Ibraham Malik, exercised stock options and simultaneously sold shares on August 5, 2025.

Cytokinetics President and CEO Robert I. Blum sold 5,000 shares of common stock for $36.45 per share in a transaction executed under a Rule 10b5-1 trading plan.

A Cytokinetics executive exercised stock options and simultaneously sold an equivalent number of shares as part of a pre-arranged trading plan.

Cytokinetics Inc. Director John T. Henderson acquired 559 shares of common stock at $38.01 per share as part of an equity in lieu of cash retainer program.

Cytokinetics Director Nancy Wysenski acquired 164 shares of common stock at $38.01 per share on July 15, 2025, as part of a director equity in lieu of cash retainer program.

Cytokinetics Inc. Director Wendall Wierenga acquired 164 shares of common stock at $38.01 per share as part of a director equity program, increasing total beneficial ownership to 32,345 shares.

Cytokinetics Director Edward M. Kaye, MD, acquired 328 shares of common stock at $38.01 per share as part of the director equity program.

Cytokinetics Director Robert Arthur Harrington acquired 328 shares of common stock as part of the company's director equity in lieu of cash retainer program.

Cytokinetics President and CEO Robert Blum has filed a Form 4 indicating a future sale of 5,000 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

A Cytokinetics executive, Fady Ibraham Malik, exercised stock options and subsequently sold 2,000 shares of common stock for a profit, as disclosed in a recent SEC Form 4 filing.

Cytokinetics Inc.'s President and CEO, Robert I. Blum, sold 5,000 shares of common stock for $33.55 per share on July 1, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics EVP of Research & Development, Fady Ibraham Malik, exercised stock options and subsequently sold an equal number of shares on June 17, 2025, under a Rule 10b5-1 trading plan.

Robert I. Blum, President and CEO of Cytokinetics Inc., has sold 5,000 shares of common stock at $33.8 per share, executed under a Rule 10b5-1 trading plan.

Edward M. Kaye, a Director at Cytokinetics Inc. (CYTK), has sold 3,636 shares of common stock at a price of $32.1 per share, as part of a pre-arranged Rule 10b5-1 trading plan.

Cytokinetics' EVP, Chief Commercial Officer, Andrew Callos, sold 8,659 shares of common stock for $32.04 per share on June 5, 2025, under a Rule 10b5-1 trading plan.

Fady Ibraham Malik, EVP Research & Development at Cytokinetics Inc., executed a pre-planned transaction on June 3, 2025, exercising stock options and simultaneously selling an equal number of common shares.

Cytokinetics' Executive Vice President and Chief Financial Officer, Lee Sung, reported a routine disposition of 4,965 shares of common stock for tax withholding purposes following the vesting of restricted stock units.

Cytokinetics Inc.'s President and CEO, Robert I. Blum, reported the sale of 5,000 shares of common stock for approximately $156,100, executed under a Rule 10b5-1 trading plan.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on May 20, 2025.

Director Robert Harrington reported the acquisition of restricted stock units and stock options, as well as the disposal of common stock.

Cytokinetics' President and CEO, Robert I. Blum, sold 5,000 shares of common stock at a price of $30.93 on May 16, 2025.

Director Muna Bhanji reported selling 1,454 shares of Cytokinetics Inc. common stock on May 15, 2025.

Director Lynne Parshall reports acquisition of restricted stock units and stock options in Cytokinetics, along with disposition of common stock.

Director Muna Bhanji reports acquisition of restricted stock units and stock options, along with disposition of common stock.

Director John T. Henderson reports acquisition of Cytokinetics stock and options, including restricted stock units and non-qualified stock options, as per Form 4 filing.

Director Edward M. Kaye reports acquisition of Cytokinetics stock and options, signaling changes in beneficial ownership.

Director Robert E. Landry reports the acquisition of restricted stock units and stock options in Cytokinetics Inc.

Director Wendell Wierenga reports acquisition of Cytokinetics stock and options, including restricted stock units and non-qualified stock options, as per Form 4 filing.

Director Nancy Wysenski reports the acquisition of restricted stock units and stock options in Cytokinetics, Inc.

Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, exercised stock options and sold a portion of the acquired shares on May 6, 2025.